March 2nd, 2026 | 07:20 CET
Will the Iran conflict fuel gold prices? Iamgold and Lahontan Gold stand to benefit! Novo Nordisk shares poised for a rebound?
Will tensions in Iran push gold to new highs? At the very least, the crisis currency is likely to see renewed demand, and with it, gold stocks. Iamgold demonstrates that industry does not necessarily rely on rising gold prices to generate strong profits. Expectations for the gold producer's quarterly figures were high. Can the 50% rally continue? Lahontan Gold is currently in a pivotal phase. Its historical resource of just under 2 million ounces is expected to increase following updated estimates. In addition, the construction of the first mine in the heart of the US gold region appears increasingly likely. This may be one of the last opportunities to accumulate the stock at an attractive price. By contrast, Novo Nordisk has lost considerable investor confidence. The shares appear inexpensive, but is another guidance cut looming? Some analysts believe the stock may have already found a bottom.
time to read: 4 minutes
|
Author:
Fabian Lorenz
ISIN:
IAMGOLD CORP. | CA4509131088 , LAHONTAN GOLD CORP | CA50732M1014 | TSXV: LG , OTCQB: LGCXF , NOVO NORDISK A/S | DK0062498333
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Lahontan Gold: More than 2 million ounces in the heart of the US gold region
It may currently be one of the last opportunities to accumulate Lahontan Gold shares below CAD 1. The explorer is active in Nevada, a hotspot for precious metals in the US. The historical resource of just under 2 million ounces has long been surpassed. An update is expected to be published in the coming weeks. The market capitalization is currently less than CAD 200 million. For a company that could soon be building a mine, this seems anything but expensive.
The fact that gold deposits in North America are particularly valuable is currently demonstrated by Barrick Mining's plan to list its activities in the region as an independent company on the stock exchange. Lahontan Gold has four gold and silver properties in Nevada's famous Walker Lane area and is in a very exciting phase of development for shareholders.
Lahontan founder and CEO Kimberly Ann is bursting with energy in her interview with Lyndsay Malchuk from the International Investment Forum. She is convinced that the stock market has not yet fully priced in the company's potential. At the Santa Fe project, recent drilling has returned shallow, thick oxide gold and silver intersections. It should not be underestimated that the company has received important regulatory approvals for a significant expansion of exploration. According to Ann, this is a factor that is "not boring" in Nevada, but rather a real valuation driver.
The common thread running through the conversation is that exploration could soon turn into something more. Santa Fe already produced from the late 1980s to the early 1990s. At that time, gold was trading between USD 300 and USD 450 per ounce. In addition to intensive drilling, the company also plans to systematically evaluate historically significant material such as old tailings. This is a potentially valuable lever, especially when gold prices are high, and easier to bring into production.
The company is stepping on the gas. The final building permit for the first mine is expected to be available at the end of 2026 or in the first quarter of 2027 at the latest.
https://youtu.be/pRq4WtH82Rc?si=4VEEF_4CVRncayiQ
Iamgold: 50% price increase and strong figures
Iamgold shares are clearly among the winners of 2026. In the first two months, the gold producer's stock rose by around 50%. The market capitalization now stands at USD 14.5 billion. Expectations for the gold producer's Q4 figures were correspondingly high. And the company delivered.
Attributable gold production reached a record level of 242,400 ounces in the fourth quarter of 2025 and 765,900 ounces for the year as a whole. This was in line with the average production forecast.
The company more than doubled its revenue in Q4 from USD 469.9 million to a total of USD 1,088.1 million. To achieve this, 259,000 ounces were sold at an average realized gold price of USD 4,191 per ounce. For the full year 2025, revenues climbed from USD 1,633.0 million to USD 2,852.8 million. In 2025, 817,800 ounces were sold at an average realized gold price of USD 3,482 per ounce.
Iamgold also posted strong growth in net profit last year. In Q4 2025, this stood at USD 406.6 million. In the same quarter of the previous year, it was only USD 86.2 million. For 2025 as a whole, the company achieved a net profit of USD 664.4 million. In 2024, adjusted for the reversal of a previously recorded impairment loss, it was around USD 364.1 million.
The stock is responding to the news with slight gains. This brings the price increase over the past 12 months to 345%.
Novo Nordisk: Ready for a rebound?
While there are many reasons to expect rising prices for Lahontan Gold and Iamgold, Novo Nordisk continues to slide in the current year. In the first two months of the year, the pharmaceutical stock has already lost 28% of its value and was trading at only DKK 237.90 on Friday. In June 2024, it briefly exceeded DKK 1,000. Since then, several forecast reductions, weak study results compared to the competition, and increasing competition in weight loss injections have caused disillusionment among shareholders.
Is the worst now over? At least that is what the analysts at KM Capital believe. They recently upgraded Novo Nordisk's stock from "Sell" to "Hold." The stock would now be valued as it was before the GLP-1 hype. This could mean that it has bottomed out. However, competitive pressure remains high.
Barclays had already confirmed its "Equal Weight" recommendation. Analysts see the fair value of the pharmaceutical company's stock at DKK 270. They point to the successful launch of Wegovy in tablet form. However, they also point to increasing competition.
Lahontan Gold shares have upside potential. There are many indications that the stock will not be available for purchase below CAD 1 for much longer. Important milestones are expected to be reached in the coming months. Iamgold has already performed strongly. However, the upward trend remains intact, and gold remains the focus of investors as a crisis currency. Novo Nordisk is ripe for a rebound. However, this was also true when the share price was 30% higher. The company urgently needs to regain confidence.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
